Please wait a moment until all data is loaded. This message will disappear when all data is loaded.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
(Abz)-SKGR-SLIGK(N-[2,4-dintrophenyl]ethylenediamine)-Asp-OH
?
-
fluorescence quenched peptide spanning the PAR-2 activation site, is rapidly cleaved by KLK4
-
-
?
32 kDa enamelin + H2O
?
-
five cleavage sites on the C-terminal sides of R180, Y205, H206, M219 and R262. Kallikrein 4 digestion of the 32 kDa enamelin generates nine major cleavage products. 12 h of digestion with KLK4, all of the 32 kDa enamelin has been cleaved. Some cleavage products persist after 48 h of digestion
-
-
?
52 kDa prostatic acid phosphatase + H2O
33 kDa prostatic acid phosphatase + 19 kDa fragment
acetyl-FVQR-4-nitroanilide + H2O
acetyl-FVQR + 4-nitroaniline
-
-
-
?
amelogenin + H2O
amelogenin fragments
benzoyl-L-Ile-L-Glu-Gly-L-Arg-4-nitroanilide + H2O
benzoyl-L-Ile-L-Glu-Gly-L-Arg + 4-nitroaniline
benzyl-FVR-p-nitroanilide + H2O
?
-
-
-
-
?
benzyloxycarbonyl-FR-7-amido-4-methylcoumarin + H2O
benzyloxycarbonyl-FR + 7-amino-4-methylcoumarin
-
-
-
?
benzyloxycarbonyl-LR-7-amido-4-methylcoumarin + H2O
benzyloxycarbonyl-LR + 7-amino-4-methylcoumarin
-
-
-
?
casein + H2O
?
zymograph assay
-
-
?
collagen I + H2O
?
-
limited degradation
-
-
?
Collagen IV + H2O
?
-
limited degradation
-
-
?
D-Pro-L-Phe-L-Arg-4-nitroanilide + H2O
D-Pro-L-Phe-L-Arg + 4-nitroaniline
D-Val-L-Leu-L-Lys-4-nitroanilide + H2O
D-Val-L-Leu-L-Lys + 4-nitroaniline
D-Val-Leu-Arg-4-nitroanilide + H2O
D-Val-Leu-Arg + 4-nitroaniline
D-Val-Leu-Arg-7-amido-4-trifluoromethyl coumarin + H2O
D-Val-Leu-Arg + 7-amino-4-trifluoromethyl coumarin
-
-
-
?
EKK-7-amido-4-methylcoumarin + H2O
EKK + 7-amino-4-methylcoumarin
-
9% of the activity with VPR-7-amido-4-methylcoumarin
-
-
?
fibrinogen alpha-chain + H2O
?
-
-
-
-
?
GPR-7-amido-4-methylcoumarin + H2O
GPR + 7-amino-4-methylcoumarin
-
20% of the activity with VPR-7-amido-4-methylcoumarin
-
-
?
human ephrin-B2 + H2O
?
low activity with recombinant human enzyme and human substrate
-
-
?
matrix metalloproteinase-1 + H2O
?
murine ephrin-B2 + H2O
?
the substrate harbors N-glycosylation sites its extracellular domain sequence, R27-R178, good activity with recombinant human enzyme and murine substrate, the primary enzyme cleavage site in murine ephrin-B2 is verified as located between extracellular domain residues Arg178 and N179
cleavage fragments, overview
-
?
plasma hepatocyte growth factor activator zymogen + H2O
mature HGF activator + ?
polypeptide + H2O
peptides
pro-prostate-specific antigen + H2O
activated prostate-specific antigen
pro-urokinase-type plasminogen activator + H2O
activated urokinase-type plasminogen activator
proform of KLK3 + H2O
?
Ile-Leu-Ser-Arg-/-Ile-Val activation site
-
-
?
protease-activated receptor-1 + H2O
?
-
KLK4 cleaves protease-activated receptor-1 at the activation site on intact cell surface
-
-
?
QAR-7-amido-4-methylcoumarin + H2O
QAR + 7-amino-4-methylcoumarin
-
38% of the activity with VPR-7-amido-4-methylcoumarin
-
-
?
Tos-Gly-Pro-Arg-7-amido-4-methylcoumarin + H2O
?
-
-
-
-
?
tosyl-Gly-Pro-Arg-7-amido-4-methylcoumarin + H2O
tosyl-Gly-Pro-Arg + 7-amino-4-methylcoumarin
-
-
-
-
?
urokinase-type plasminogen activator + H2O
?
urokinase-type plasminogen activator receptor + H2
?
-
cleavage occurs in D1-D2 linker sequence and, to a lesser extent, in D3 juxtamembrane domain
-
-
?
urokinase-type plasminogen activator receptor + H2O
?
cleaves after Thr-Tyr-Ser-Arg as well as in the sequence Val-Gln-Tyr-Arg-/-Ser-Gly
-
-
?
VLK-7-amido-4-methylcoumarin + H2O
VLK + 7-amino-4-methylcoumarin
-
60% of the activity with VPR-7-amido-4-methylcoumarin
-
-
?
VPR-7-amido-4-methylcoumarin + H2O
VPR + 7-amino-4-methylcoumarin
-
-
-
-
?
Z-FVR-p-nitroanilide + H2O
Z-FVR + p-nitroaniline
-
-
-
-
?
Z-Phe-Val-Arg-p-nitroanilide + H2O
?
-
-
-
-
?
additional information
?
-
52 kDa prostatic acid phosphatase + H2O
33 kDa prostatic acid phosphatase + 19 kDa fragment
-
recombinant self-activated, chimeric enzyme
products contain 256 and 73 amino acid residues, respectively
?
52 kDa prostatic acid phosphatase + H2O
33 kDa prostatic acid phosphatase + 19 kDa fragment
-
primary cleavage site is the Arg73-Ser74 bond
products contain 256 and 73 amino acid residues, respectively
?
52 kDa prostatic acid phosphatase + H2O
33 kDa prostatic acid phosphatase + 19 kDa fragment
-
inactivation of substrate
products contain 256 and 73 amino acid residues, respectively
?
52 kDa prostatic acid phosphatase + H2O
33 kDa prostatic acid phosphatase + 19 kDa fragment
-
enzyme may be involved in the physiological clearance of prostatic acid phosphatase
-
?
amelogenin + H2O
?
-
-
-
?
amelogenin + H2O
?
the enzyme plays a pivotal role during dental enamel formation by degrading the major enamel protein, amelogenin, prior to the final steps of enamel hardening. KLK4 self-destructs once amelogenin is degraded. It progressively loses activity, becomes aggregated, and autofragmented when incubated without substrate in both the presence and absence of reducer. However, with non-ionic detergent present as proxy substrate, KLK4 remains active and intact throughout
-
-
?
amelogenin + H2O
?
-
-
-
-
?
amelogenin + H2O
amelogenin fragments
20 kDa substrate
-
-
?
amelogenin + H2O
amelogenin fragments
recombinant substrate from pig expressed in Escherichia coli strain XL-1 blue as His-tagged protein
product identification by N-terminal sequencing and mass spectrometry
?
amelogenin + H2O
amelogenin fragments
20 kDa substrate
-
-
?
benzoyl-L-Ile-L-Glu-Gly-L-Arg-4-nitroanilide + H2O
benzoyl-L-Ile-L-Glu-Gly-L-Arg + 4-nitroaniline
-
recombinant self-activated, chimeric enzyme
-
-
?
benzoyl-L-Ile-L-Glu-Gly-L-Arg-4-nitroanilide + H2O
benzoyl-L-Ile-L-Glu-Gly-L-Arg + 4-nitroaniline
-
fluorogenic substrate, i.e. S-2222
-
-
?
D-Pro-L-Phe-L-Arg-4-nitroanilide + H2O
D-Pro-L-Phe-L-Arg + 4-nitroaniline
-
recombinant self-activated, chimeric enzyme
-
-
?
D-Pro-L-Phe-L-Arg-4-nitroanilide + H2O
D-Pro-L-Phe-L-Arg + 4-nitroaniline
-
fluorogenic substrate, i.e. S-2302
-
-
?
D-Val-L-Leu-L-Lys-4-nitroanilide + H2O
D-Val-L-Leu-L-Lys + 4-nitroaniline
-
recombinant self-activated, chimeric enzyme
-
-
?
D-Val-L-Leu-L-Lys-4-nitroanilide + H2O
D-Val-L-Leu-L-Lys + 4-nitroaniline
-
fluorogenic substrate, i.e. S-2251
-
-
?
D-Val-Leu-Arg-4-nitroanilide + H2O
D-Val-Leu-Arg + 4-nitroaniline
-
recombinant self-activated, chimeric enzyme
-
-
?
D-Val-Leu-Arg-4-nitroanilide + H2O
D-Val-Leu-Arg + 4-nitroaniline
-
fluorogenic substrate, i.e. S-2266
-
-
?
Gelatin + H2O
?
zymograph assay
-
-
?
Gelatin + H2O
?
-
zymograph assay
-
-
?
Gelatin + H2O
?
zymograph assay
-
-
?
matrix metalloproteinase-1 + H2O
?
-
-
-
?
matrix metalloproteinase-1 + H2O
?
the enzyme activates matrix metalloproteinase-1, a protease that promotes prostate tumor growth and metastasis. Matrix metalloproteinase-1 is produced in the tumor compartment of prostate cancer bone metastases, highlighting its accessibility to KLK4 at this site
-
-
?
plasma hepatocyte growth factor activator zymogen + H2O
mature HGF activator + ?
activation, hepatocyte growth factor is mainly secreted from fibroblasts as an inactive single-chain precursor, which lacks biological activity
-
-
?
plasma hepatocyte growth factor activator zymogen + H2O
mature HGF activator + ?
conversion to an active two-chain form
-
-
?
polypeptide + H2O
peptides
-
-
-
?
polypeptide + H2O
peptides
-
-
?
polypeptide + H2O
peptides
-
-
?
polypeptide + H2O
peptides
-
-
?
polypeptide + H2O
peptides
-
-
?
polypeptide + H2O
peptides
-
-
?
polypeptide + H2O
peptides
enzyme is involved in degradation of extracellular matrix and activation of prostate specific antigen PSA and other proteases
-
?
polypeptide + H2O
peptides
enzyme is regulated by steroid hormones
-
?
polypeptide + H2O
peptides
enzyme may be involved in the pathogenesis and/or progression of prostate, breast, and possibly other malgnancies
-
?
polypeptide + H2O
peptides
-
enzyme plays a role in the physiologic processing of seminal plasma proteins , e.g. pro-PSA, as well as in the pathogenesis of prostate cancer through the activation of pro-PSA
-
?
polypeptide + H2O
peptides
Q9JIS2
-
-
?
polypeptide + H2O
peptides
-
-
?
polypeptide + H2O
peptides
-
-
?
polypeptide + H2O
peptides
-
-
?
pro-prostate-specific antigen + H2O
activated prostate-specific antigen
-
activation of substrate
-
?
pro-prostate-specific antigen + H2O
activated prostate-specific antigen
-
recombinant self-activated, chimeric enzyme
-
?
pro-prostate-specific antigen + H2O
activated prostate-specific antigen
-
i.e. PSA
-
?
pro-prostate-specific antigen + H2O
activated prostate-specific antigen
-
activation of PSA
-
?
pro-urokinase-type plasminogen activator + H2O
activated urokinase-type plasminogen activator
-
activation of substrate
-
?
pro-urokinase-type plasminogen activator + H2O
activated urokinase-type plasminogen activator
-
recombinant self-activated, chimeric enzyme
-
?
pro-urokinase-type plasminogen activator + H2O
activated urokinase-type plasminogen activator
-
i.e. pro-uPA
-
?
thrombospondin-1 + H2O
?
-
-
-
?
thrombospondin-1 + H2O
?
the enzyme liberates an N-terminal product, with purported angiogenic activity, from thrombospondin-1. It cleaves thrombospondin-1 in osteoblast-derived matrix
-
-
?
urokinase-type plasminogen activator + H2O
?
-
-
-
?
urokinase-type plasminogen activator + H2O
?
cleaves after Pro-Arg-Phe-Lys
-
-
?
additional information
?
-
-
no activity with serum albumin from human seminal plasma
-
-
?
additional information
?
-
-
enzyme has a trypsin-type substrate specificty
-
-
?
additional information
?
-
-
no activity with pyroglu-Gly-Arg-4-nitroanilide, i.e. S-2444, and with 3-carbomethoxypropionyl-L-Arg-L-Pro-L-Tyr-4-nitroanilide, i.e. S-2586
-
-
?
additional information
?
-
enzyme is regulated by steroid hormones, contains androgen response elements in the proximal promotor region
-
-
?
additional information
?
-
-
enzyme is involved in tissue remodeling and cancer metastasis
-
-
?
additional information
?
-
-
enzyme modulates the tumor-associated urokinase-type plasminogen activator/urokinase-type plasminogen activator receptor system activity by either activating the pro-enzyme form of urokinase-type plasminogen activator or cleaving the cell surface-associated urokinase-type plasminogen activator receptor
-
-
?
additional information
?
-
-
enzyme cleaves more efficiently after Arg compared to Lys at the P1 position and exhibits modest specificity for amino acids at P2 and P3 positions
-
-
?
additional information
?
-
clearly prefers P1-Arg over Lys and Tyr
-
-
?
additional information
?
-
-
KLK4 initiates phosphorylation of ERK1/2 via PAR-2
-
-
?
additional information
?
-
kallikrein-4 is a serine protease expressed during enamel maturation, and proteolytic processing of the enamel matrix by KLK4 is critical for proper enamel formation. In vitro dipeptidyl peptidase I activates pro-KLK4 to cleave a fluorogenic peptide containing a KLK4 cleavage site
-
-
?
additional information
?
-
preference for Arg over Lys at position P1. KLK4 prefers as P2 residue the medium-sized polar Gln over the more hydrophobic Val, Leu, Thr, and Pro, whereas large aromatic and basic side chains are not accepted. Marked specificity for medium-sized to large hydrophobic P4 residues. Activation cleavage site: SCSQ-IING
-
-
?
additional information
?
-
two proteases are secreted into the enamel matrix of developing teeth. The early protease is enamelysin (MMP-20). The late protease is kallikrein 4. KLK4 aggressively degrades the retained organic matrix following the termination of enamel protein secretion. The principle functions of MMP-20 and KLK4 in dental enamel formation are to facilitate the orderly replacement of organic matrix with mineral, generating an enamel layer that is harder, less porous, and unstained by retained enamel proteins
-
-
?
additional information
?
-
the enzyme performs proteolytic autoactivation
-
-
?
additional information
?
-
-
the enzyme performs proteolytic autoactivation
-
-
?
additional information
?
-
position of predicted enzyme cleavage sites within the sequence and the folded protein, structure, overview
-
-
?
additional information
?
-
-
position of predicted enzyme cleavage sites within the sequence and the folded protein, structure, overview
-
-
?
additional information
?
-
recombinant zymogen can be activated by thermolysin
-
-
?
additional information
?
-
-
recombinant zymogen can be activated by thermolysin
-
-
?
additional information
?
-
enzyme participates in the degradation of enamel proteins in vivo
-
-
?
additional information
?
-
-
enzyme participates in the degradation of enamel proteins in vivo
-
-
?
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Adenocarcinoma
Kallikrein 4 is expressed in malignant mesothelioma--further evidence for the histogenetic link between mesothelial and epithelial cells.
Adenocarcinoma
Kallikrein-related peptidase 4 (KLK4) mRNA predicts short-term relapse in colorectal adenocarcinoma patients.
Amelogenesis Imperfecta
Human enamel phenotype associated with amelogenesis imperfecta and a kallikrein-4 (g.2142G>A) proteinase mutation.
Amelogenesis Imperfecta
Hypomaturation enamel defects in Klk4 knockout/LacZ knockin mice.
Amelogenesis Imperfecta
MMP20 hemopexin domain mutation in amelogenesis imperfecta.
Amelogenesis Imperfecta
Mutation in kallikrein 4 causes autosomal recessive hypomaturation amelogenesis imperfecta.
Amelogenesis Imperfecta
Premature stop codon in MMP20 causing amelogenesis imperfecta.
Breast Neoplasms
Specific increase of human kallikrein 4 mRNA and protein levels in breast cancer stromal cells.
Carcinogenesis
Kallikrein-related peptidase signaling in colon carcinoma cells: Targeting proteinase-activated receptors (PARs).
Carcinogenesis
MiR-378a-5p inhibits angiogenesis of oral squamous cell carcinoma by targeting KLK4.
Carcinoma
Human kallikrein 4 (KLK4) is highly expressed in serous ovarian carcinomas.
Carcinoma
Kallikrein 4 expression is up-regulated in epithelial ovarian carcinoma cells in effusions.
Carcinoma
Kallikrein-related peptidase 4 contributes to the tumor metastasis of oral squamous cell carcinoma.
Carcinoma
Low mRNA expression levels of kallikrein-related peptidase 4 (KLK4) predict short-term relapse in patients with laryngeal squamous cell carcinoma.
Carcinoma, Ovarian Epithelial
Kallikrein 4 expression is up-regulated in epithelial ovarian carcinoma cells in effusions.
Carcinoma, Squamous Cell
Elevated levels of both microRNA 378 (miR-378) and kallikrein-related peptidase 4 (KLK4) mRNA are associated with an unfavorable prognosis in triple-negative breast cancer.
Colonic Neoplasms
Kallikrein-related peptidase 4: a new activator of the aberrantly expressed protease-activated receptor 1 in colon cancer cells.
Endometrial Neoplasms
Kallikrein 4 (KLK4), a new member of the human kallikrein gene family is up-regulated by estrogen and progesterone in the human endometrial cancer cell line, KLE.
Endometrial Neoplasms
Kallikrein 4 overexpression in endometrial carcinoma and upregulation by estrogen via mitogen-activated protein kinase signal pathway.
Endometriosis
Kallikrein-related peptidase 4 promotes migration and invasion of endometrial stromal cells in endometriosis by inducing epithelial-mesenchymal transition.
Hepatitis C
Mannan binding lectin-associated serine protease 1 is induced by hepatitis C virus infection and activates human hepatic stellate cells.
Hepatitis C
Severe fibrosis in hepatitis C virus-infected patients is associated with increased activity of the mannan-binding lectin (MBL)/MBL-associated serine protease 1 (MASP-1) complex.
Infections
Identification of a Highly Antigenic Region of Subtilisin-Like Serine Protease 1 for Serodiagnosis of Neospora caninum Infection.
Leukoencephalopathies
A Case of Cerebral Small Vessel Disease Related to a Heterozygous Nonsense Mutation in HTRA1.
Leukoencephalopathies
Genetically Confirmed CARASIL: Case Report with Novel HTRA1 Mutation and Literature Review.
Lupus Nephritis
Micro-RNA analysis of renal biopsies in human lupus nephritis demonstrates up-regulated miR-422a driving reduction of kallikrein-related peptidase 4.
Lupus Nephritis
Role of miR-422a and kallikrein-related peptidase 4 implicated in the development of lupus nephritis. Do we work in this direction?
Mesothelioma, Malignant
Kallikrein 4 is expressed in malignant mesothelioma--further evidence for the histogenetic link between mesothelial and epithelial cells.
Mouth Neoplasms
Clinical significance of kallikrein-related peptidase-4 in oral cancer.
Neoplasm Metastasis
A KLK4 proteinase substrate capture approach to antagonize PAR1.
Neoplasm Metastasis
Kallikrein-related peptidase 4 contributes to the tumor metastasis of oral squamous cell carcinoma.
Neoplasm Metastasis
MiR-378a-5p inhibits angiogenesis of oral squamous cell carcinoma by targeting KLK4.
Neoplasm Metastasis
Prostate Cancer-Associated Kallikrein-Related Peptidase 4 Activates Matrix Metalloproteinase-1 and Thrombospondin-1.
Neoplasms
A KLK4 proteinase substrate capture approach to antagonize PAR1.
Neoplasms
Aberrant KLK4 gene promoter hypomethylation in pediatric hepatoblastomas.
Neoplasms
Characterization of kallikrein-related peptidase 4 (KLK4) mRNA expression in tumor tissue of advanced high-grade serous ovarian cancer patients.
Neoplasms
Comparative Temporospatial Expression Profiling of Murine Amelotin Protein during Amelogenesis.
Neoplasms
Direct progesterone receptor and indirect androgen receptor interactions with the kallikrein-related peptidase 4 gene promoter in breast and prostate cancer.
Neoplasms
Elevated levels of both microRNA 378 (miR-378) and kallikrein-related peptidase 4 (KLK4) mRNA are associated with an unfavorable prognosis in triple-negative breast cancer.
Neoplasms
Kallikrein 4 is a potential mediator of cellular interactions between cancer cells and osteoblasts in metastatic prostate cancer.
Neoplasms
Kallikrein 4 is expressed in malignant mesothelioma--further evidence for the histogenetic link between mesothelial and epithelial cells.
Neoplasms
Kallikrein-related peptidase 4 (KLK4) initiates intracellular signaling via protease-activated receptors (PARs). KLK4 and PAR-2 are co-expressed during prostate cancer progression.
Neoplasms
Kallikrein-related peptidase 4 contributes to the tumor metastasis of oral squamous cell carcinoma.
Neoplasms
Kallikrein-related peptidase 4 gene (KLK4) in prostate tumors: Quantitative expression analysis and evaluation of its clinical significance.
Neoplasms
Kallikrein-related peptidase 4 promotes migration and invasion of endometrial stromal cells in endometriosis by inducing epithelial-mesenchymal transition.
Neoplasms
Kallikrein-related peptidase signaling in colon carcinoma cells: Targeting proteinase-activated receptors (PARs).
Neoplasms
KLK4 Induces Anti-Tumor Effects in Human Xenograft Mouse Models of Orthotopic and Metastatic Prostate Cancer.
Neoplasms
MiR-378a-5p inhibits angiogenesis of oral squamous cell carcinoma by targeting KLK4.
Neoplasms
Ovarian cancer specific kallikrein profile in effusions.
Odontogenic Tumors
Kallikrein 4 and matrix metalloproteinase-20 immunoexpression in malignant, benign and infiltrative odontogenic tumors.
Ovarian Neoplasms
Characterization of kallikrein-related peptidase 4 (KLK4) mRNA expression in tumor tissue of advanced high-grade serous ovarian cancer patients.
Ovarian Neoplasms
Kallikrein 4 is associated with paclitaxel resistance in ovarian cancer.
Ovarian Neoplasms
Ovarian cancer specific kallikrein profile in effusions.
Ovarian Neoplasms
Paclitaxel resistance and multicellular spheroid formation are induced by kallikrein-related peptidase 4 in serous ovarian cancer cells in an ascites mimicking microenvironment.
Pancreatic Neoplasms
PRSS1 mutations and the proteinase/antiproteinase imbalance in the pathogenesis of pancreatic cancer.
Pancreatitis
Hereditary pancreatitis for the endoscopist.
Pancreatitis
High Incidence of PRSS1 and SPINK1 Mutations in Korean Children With Acute Recurrent and Chronic Pancreatitis.
Pancreatitis
Human cationic trypsinogen (PRSS1) variants and chronic pancreatitis.
Pancreatitis, Chronic
High Incidence of PRSS1 and SPINK1 Mutations in Korean Children With Acute Recurrent and Chronic Pancreatitis.
Pancreatitis, Chronic
Human cationic trypsinogen (PRSS1) variants and chronic pancreatitis.
Pancreatitis, Chronic
Mutation That Promotes Activation of Trypsinogen Increases Severity of Secretagogue-Induced Pancreatitis in Mice.
Prostatic Neoplasms
Compartmentalized expression of kallikrein 4 (KLK4/hK4) isoforms in prostate cancer: nuclear, cytoplasmic and secreted forms.
Prostatic Neoplasms
Crystal structure of the inhibitor-free form of the serine protease kallikrein-4.
Prostatic Neoplasms
Detection of human kallikrein 4 in healthy and cancerous prostatic tissues by immunofluorometry and immunohistochemistry.
Prostatic Neoplasms
Direct progesterone receptor and indirect androgen receptor interactions with the kallikrein-related peptidase 4 gene promoter in breast and prostate cancer.
Prostatic Neoplasms
Epithelial-mesenchymal transition in prostate cancer and the potential role of kallikrein serine proteases.
Prostatic Neoplasms
Expression of human kallikrein 1-related peptidase 4 (KLK4) and MET phosphorylation in prostate cancer tissue: immunohistochemical analysis.
Prostatic Neoplasms
Human kallikrein 4 signal peptide induces cytotoxic T cell responses in healthy donors and prostate cancer patients.
Prostatic Neoplasms
Kallikrein 4 (hK4) and prostate-specific antigen (PSA) are associated with the loss of E-cadherin and an epithelial-mesenchymal transition (EMT)-like effect in prostate cancer cells.
Prostatic Neoplasms
Kallikrein 4 is a potential mediator of cellular interactions between cancer cells and osteoblasts in metastatic prostate cancer.
Prostatic Neoplasms
Kallikrein 4 is a predominantly nuclear protein and is overexpressed in prostate cancer.
Prostatic Neoplasms
Kallikrein 4 is a proliferative factor that is overexpressed in prostate cancer.
Prostatic Neoplasms
Kallikrein-related peptidase 4 (KLK4) initiates intracellular signaling via protease-activated receptors (PARs). KLK4 and PAR-2 are co-expressed during prostate cancer progression.
Prostatic Neoplasms
Kallikrein-related peptidase-4 initiates tumor-stroma interactions in prostate cancer through protease-activated receptor-1.
Prostatic Neoplasms
KLK4 Induces Anti-Tumor Effects in Human Xenograft Mouse Models of Orthotopic and Metastatic Prostate Cancer.
Prostatic Neoplasms
Mastering the canonical loop of serine protease inhibitors: enhancing potency by optimising the internal hydrogen bond network.
Prostatic Neoplasms
Murine, but not human, ephrin-B2 can be efficiently cleaved by the serine protease kallikrein-4: Implications for xenograft models of human prostate cancer.
Prostatic Neoplasms
Polyclonal antibodies against kallikrein-related peptidase 4 (KLK4): immunohistochemical assessment of KLK4 expression in healthy tissues and prostate cancer.
Prostatic Neoplasms
Potent, Selective, and Cell-Penetrating Inhibitors of Kallikrein-Related Peptidase 4 Based on the Cyclic Peptide MCoTI-II.
Prostatic Neoplasms
Prostate Cancer-Associated Kallikrein-Related Peptidase 4 Activates Matrix Metalloproteinase-1 and Thrombospondin-1.
Prostatic Neoplasms
Substrate-guided design of a potent and selective kallikrein-related peptidase inhibitor for kallikrein 4.
Sepsis
Identification of Potential Biomarkers by Serum Proteomics Analysis in Rats With Sepsis.
Squamous Cell Carcinoma of Head and Neck
Kallikrein-related peptidase 4 contributes to the tumor metastasis of oral squamous cell carcinoma.
Squamous Cell Carcinoma of Head and Neck
Low mRNA expression levels of kallikrein-related peptidase 4 (KLK4) predict short-term relapse in patients with laryngeal squamous cell carcinoma.
Triple Negative Breast Neoplasms
Elevated levels of both microRNA 378 (miR-378) and kallikrein-related peptidase 4 (KLK4) mRNA are associated with an unfavorable prognosis in triple-negative breast cancer.
Triple Negative Breast Neoplasms
Tissue kallikrein-related peptidase 4 (KLK4), a novel biomarker in triple-negative breast cancer.
Virus Diseases
Mannan binding lectin-associated serine protease 1 is induced by hepatitis C virus infection and activates human hepatic stellate cells.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Boeckmann, B.; Bairoch, A.; Apweiler, R.; Blatter, M.C.; Estreicher, A.; Gasteiger, E.; Martin M.J.; Michoud, K.; O'Donovan, C.; Phan, I.; Pilbout, S.; Schneider, M.
The SWISS-PROT protein knowledgebase and its supplement TrEMBL
Nucleic Acids Res.
31
365-370
2003
Homo sapiens (Q9Y5K2)
brenda
Yousef, G.M.; Diamandis, E.P.
The new human tissue kallikrein gene family: structure, function, and association to disease
Endocr. Rev.
22
184-204
2001
Homo sapiens (Q9Y5K2)
brenda
Simmer, J.P.; Fukae, M.; Tanabe, T.; Yamakoshi, Y.; Uchida, T.; Xue, J.; Margolis, H.C.; Shimizu, M.; DeHart, B.C.; Hu, J.C.C.; Bartlett, J.D.
Purification, characterization, and cloning of enamel matrix serine proteinase 1
J. Dent. Res.
77
377-386
1998
Sus scrofa (Q9XSN6), Sus scrofa, Sus scrofa EMSP1 (Q9XSN6)
brenda
Yousef, G.M.; Obiezu, C.V.; Luo, L.Y.; Black, M.H.; Diamandis, E.P.
Prostase/KLK-L1 is a new member of the human kallikrein gene family, is expressed in prostate and breast tissues, and is hormonally regulated
Cancer Res.
59
4252-4256
1999
Homo sapiens (Q9Y5K2), Homo sapiens
brenda
Stephenson, S.A.; Verity, K.; Ashworth, L.K.; Clements, J.A.
Localization of a new prostate-specific antigen-related serine protease gene, KLK4, is evidence for an expanded human kallikrein gene family cluster on chromosome 19q13.3-13.4
J. Biol. Chem.
274
23210-23214
1999
Homo sapiens (Q9Y5K2)
brenda
Nelson, P.S.; Gan, L.; Ferguson, C.; Moss, P.; Gelinas, R.; Hood, L.; Wang, K.
Molecular cloning and characterization of prostase, an androgen-regulated serine protease with prostate-restricted expression
Proc. Natl. Acad. Sci. USA
96
3114-3119
1999
Homo sapiens (Q9Y5K2), Homo sapiens
brenda
Hu, J.C.C.; Zhang, C.; Sun, X.; Yang, Y.; Cao, X.; Ryu, O.; Simmer, J.P.
Characterization of the mouse and human PRSS17 genes, their relationship to other serine proteases, and the expression of PRSS17 in developing mouse incisors
Gene
251
1-8
2000
Mus musculus (Q9JIS2), Mus musculus, Homo sapiens (Q9Y5K2), Homo sapiens
brenda
Takayama, T.K.; McMullen, B.A.; Nelson, P.S.; Matsumura, M.; Fujikawa, K.
Characterization of hK4 (prostase), a prostate-specific serine protease: activation of the precursor of prostate specific antigen (pro-PSA) and single-chain urokinase-type plasminogen activator and degradation of prostatic acid phosphatase
Biochemistry
40
15341-15348
2001
Homo sapiens
brenda
Ryu, O.; Hu, J.C.; Yamakoshi, Y.; Villemain, J.L.; Cao, X.; Zhang, C.; Bartlett, J.D.; Simmer, J.P.
Porcine kallikrein-4 activation, glycosylation, activity, and expression in prokaryotic and eukaryotic hosts
Eur. J. Oral Sci.
110
358-365
2002
Sus scrofa (Q9XSN6), Sus scrofa
brenda
Beaufort, N.; Debela, M.; Creutzburg, S.; Kellermann, J.; Bode, W.; Schmitt, M.; Pidard, D.; Magdolen, V.
Interplay of human tissue kallikrein 4 (hK4) with the plasminogen activation system: hK4 regulates the structure and functions of the urokinase-type plasminogen activator receptor (uPAR)
Biol. Chem.
387
217-222
2006
Homo sapiens
brenda
Prezas, P.; Arlt, M.J.; Viktorov, P.; Soosaipillai, A.; Holzscheiter, L.; Schmitt, M.; Talieri, M.; Diamandis, E.P.; Krueger, A.; Magdolen, V.
Overexpression of the human tissue kallikrein genes KLK4, 5, 6, and 7 increases the malignant phenotype of ovarian cancer cells
Biol. Chem.
387
807-811
2006
Homo sapiens
brenda
Davidson, B.; Xi, Z.; Klokk, T.I.; Trope, C.G.; D?rum, A.; Scheistr?en, M.; Saatcioglu, F.
Kallikrein 4 expression is up-regulated in epithelial ovarian carcinoma cells in effusions
Am. J. Clin. Pathol.
123
360-368
2005
Homo sapiens
brenda
Obiezu, C.V.; Michael, I.P.; Levesque, M.A.; Diamandis, E.P.
Human kallikrein 4: enzymatic activity, inhibition, and degradation of extracellular matrix proteins
Biol. Chem.
387
749-759
2006
Homo sapiens
brenda
Xi, Z.; Klokk, T.I.; Korkmaz, K.; Kurys, P.; Elbi, C.; Risberg, B.; Danielsen, H.; Loda, M.; Saatcioglu, F.
Kallikrein 4 is a predominantly nuclear protein and is overexpressed in prostate cancer
Cancer Res.
64
2365-2370
2004
Homo sapiens
brenda
Obiezu, C.V.; Shan, S.J.; Soosaipillai, A.; Luo, L.Y.; Grass, L.; Sotiropoulou, G.; Petraki, C.D.; Papanastasiou, P.A.; Levesque, M.A.; Diamandis, E.P.
Human kallikrein 4: quantitative study in tissues and evidence for its secretion into biological fluids
Clin. Chem.
51
1432-1442
2005
Homo sapiens
brenda
Hart, P.S.; Hart, T.C.; Michalec, M.D.; Ryu, O.H.; Simmons, D.; Hong, S.; Wright, J.T.
Mutation in kallikrein 4 causes autosomal recessive hypomaturation amelogenesis imperfecta
J. Med. Genet.
41
545-549
2004
Homo sapiens
brenda
Westermann, D.; Schultheiss, H.P.; Tschoepe, C.
New perspective on the tissue kallikrein-kinin system in myocardial infarction: role of angiogenesis and cardiac regeneration
Int. Immunopharmacol.
8
148-154
2008
Homo sapiens
brenda
Debela, M.; Magdolen, V.; Schechter, N.; Valachova, M.; Lottspeich, F.; Craik, C.S.; Choe, Y.; Bode, W.; Goettig, P.
Specificity profiling of seven human tissue kallikreins reveals individual subsite preferences
J. Biol. Chem.
281
25678-25688
2006
Homo sapiens (Q9Y5K2)
brenda
Debela, M.; Magdolen, V.; Grimminger, V.; Sommerhoff, C.; Messerschmidt, A.; Huber, R.; Friedrich, R.; Bode, W.; Goettig, P.
Crystal structures of human tissue kallikrein 4: activity modulation by a specific zinc binding site
J. Mol. Biol.
362
1094-1107
2006
Homo sapiens
brenda
Fernando, S.C.; Buck, J.S.; Ashworth, M.D.; Ross, J.W.; Geisert, R.D.; DeSilva, U.
Porcine endometrial and conceptus tissue kallikrein 1, 4, 11, and 14 gene expression
Reproduction
132
939-947
2006
Sus scrofa
brenda
Klokk, T.I.; Kilander, A.; Xi, Z.; Waehre, H.; Risberg, B.; Danielsen, H.E.; Saatcioglu, F.
Kallikrein 4 is a proliferative factor that is overexpressed in prostate cancer
Cancer Res.
67
5221-5230
2007
Homo sapiens
brenda
Davidson, B.; Xi, Z.; Saatcioglu, F.
Kallikrein 4 is expressed in malignant mesothelioma--further evidence for the histogenetic link between mesothelial and epithelial cells
Diagn. Cytopathol.
35
80-84
2007
Homo sapiens
brenda
Wright, J.T.; Daly, B.; Simmons, D.; Hong, S.; Hart, S.P.; Hart, T.C.; Atsawasuwan, P.; Yamauchi, M.
Human enamel phenotype associated with amelogenesis imperfecta and a kallikrein-4 (g.2142G>A) proteinase mutation
Eur. J. Oral Sci.
114 Suppl 1; 13-7
discussion 39-41, 379
2006
Homo sapiens
brenda
Yamakoshi, Y.; Hu, J.C.; Fukae, M.; Yamakoshi, F.; Simmer, J.P.
How do enamelysin and kallikrein 4 process the 32-kDa enamelin?
Eur. J. Oral Sci.
114 Suppl 1; 45-51; discussion 93-5
379-80
2006
Sus scrofa
brenda
Ramsay, A.J.; Dong, Y.; Hunt, M.L.; Linn, M.; Samaratunga, H.; Clements, J.A.; Hooper, J.D.
Kallikrein-related peptidase (KLK) 4 initiates intracellular signalling via protease-activated receptors (PARs). KLK4 and PAR-2 are co-expressed during prostate cancer progression
J. Biol. Chem.
283
12293-12304
2008
Homo sapiens
brenda
Gao, J.; Collard, R.L.; Bui, L.; Herington, A.C.; Nicol, D.L.; Clements, J.A.
Kallikrein 4 is a potential mediator of cellular interactions between cancer cells and osteoblasts in metastatic prostate cancer
Prostate
67
348-360
2007
Homo sapiens
brenda
Debela, M.; Beaufort, N.; Magdolen, V.; Schechter, N.M.; Craik, C.S.; Schmitt, M.; Bode, W.; Goettig, P.
Structures and specificity of the human kallikrein-related peptidases KLK 4, 5, 6, and 7
Biol. Chem.
389
623-632
2008
Homo sapiens (Q9Y5K2)
brenda
Lu, Y.; Papagerakis, P.; Yamakoshi, Y.; Hu, J.C.; Bartlett, J.D.; Simmer, J.P.
Functions of KLK4 and MMP-20 in dental enamel formation
Biol. Chem.
389
695-700
2008
Homo sapiens (Q9Y5K2)
brenda
Tye, C.E.; Pham, C.T.; Simmer, J.P.; Bartlett, J.D.
DPPI may activate KLK4 during enamel formation
J. Dent. Res.
88
323-327
2009
Homo sapiens (Q9Y5K2)
brenda
Wang, W.; Mize, G.J.; Zhang, X.; Takayama, T.K.
Kallikrein-related peptidase-4 initiates tumor-stroma interactions in prostate cancer through protease-activated receptor-1
Int. J. Cancer
126
599-610
2010
Homo sapiens
brenda
Avgeris, M.; Stravodimos, K.; Scorilas, A.
Kallikrein-related peptidase 4 gene (KLK4) in prostate tumors: quantitative expression analysis and evaluation of its clinical significance
Prostate
71
1780-1789
2011
Homo sapiens
brenda
Lisle, J.E.; Mertens-Walker, I.; Stephens, C.R.; Stansfield, S.H.; Clements, J.A.; Herington, A.C.; Stephenson, S.A.
Murine, but not human, ephrin-B2 can be efficiently cleaved by the serine protease kallikrein-4: implications for xenograft models of human prostate cancer
Exp. Cell Res.
333
136-146
2015
Homo sapiens (Q9YSK2), Homo sapiens
brenda
Mukai, S.; Yorita, K.; Yamasaki, K.; Nagai, T.; Kamibeppu, T.; Sugie, S.; Kida, K.; Onizuka, C.; Tsukino, H.; Kamimura, T.; Kamoto, T.; Kataoka, H.
Expression of human kallikrein 1-related peptidase 4 (KLK4) and MET phosphorylation in prostate cancer tissue: immunohistochemical analysis
Hum. Cell
28
133-142
2015
Homo sapiens (Q9YSK2), Homo sapiens
brenda
Swedberg, J.E.; Ghani, H.A.; Harris, J.M.; de Veer, S.J.; Craik, D.J.
Potent, selective, and cell-penetrating inhibitors of kallikrein-related peptidase 4 based on the cyclic peptide MCoTI-II
ACS Med. Chem. Lett.
9
1258-1262
2018
Homo sapiens (Q9Y5K2), Homo sapiens
brenda
Papagerakis, P.; Pannone, G.; Zheng, L.I.; Athanassiou-Papaefthymiou, M.; Yamakoshi, Y.; McGuff, H.S.; Shkeir, O.; Ghirtis, K.; Papagerakis, S.
Clinical significance of kallikrein-related peptidase-4 in oral cancer
Anticancer Res.
35
1861-1866
2015
Homo sapiens (Q9Y5K2), Homo sapiens
brenda
Perez, V.; Mangum, J.; Hubbard, M.
Direct evidence that KLK4 is a hydroxyapatite-binding protein
Biochem. Biophys. Res. Commun.
495
1896-1900
2017
Homo sapiens (Q9Y5K2)
brenda
Yang, F.; Aubele, M.; Walch, A.; Gross, E.; Napieralski, R.; Zhao, S.; Ahmed, N.; Kiechle, M.; Reuning, U.; Dorn, J.; Sweep, F.; Magdolen, V.; Schmitt, M.
Tissue kallikrein-related peptidase 4 (KLK4), a novel biomarker in triple-negative breast cancer
Biol. Chem.
398
1151-1164
2017
Homo sapiens (Q9Y5K2), Homo sapiens
brenda
Wang, L.; Xie, X.; Sun, Y.; Wang, J.; Wang, Y.; Wang, X.
KLK4 is synchronically expressed to CTSC in ameloblasts during amelogenesis molars
Int. J. Clin. Exp. Pathol.
10
5751-5757
2017
Mus musculus (Q9Z0M1)
-
brenda
Fuhrman-Luck, R.A.; Stansfield, S.H.; Stephens, C.R.; Loessner, D.; Clements, J.A.
Prostate cancer-associated kallikrein-related peptidase 4 activates matrix metalloproteinase-1 and thrombospondin-1
J. Proteome Res.
15
2466-2478
2016
Homo sapiens (Q9Y5K2)
brenda
Vickers, A.; Vertosick, E.A.; Sjoberg, D.D.; Roobol, M.J.; Hamdy, F.; Neal, D.; Bjartell, A.; Hugosson, J.; Donovan, J.L.; Villers, A.; Zappala, S.; Lilja, H.
Properties of the 4-kallikrein panel outside the diagnostic gray zone meta-analysis of patients with positive digital rectal examination or prostate specific antigen 10 ng/ml and above
J. Urol.
197
607-613
2017
Homo sapiens (Q9Y5K2)
brenda